Company news
Kailera Therapeutics, Inc. (NASDAQ:KLRA) news
Kailera Therapeutics, Inc. news releases on 6ix. Latest, Oct 1, 2026: Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting
Press releases & updates
Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting
September 30, 2026
Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting
October 1, 2026
Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection
September 30, 2026
Kailera Therapeutics to Participate in September Investor Conferences
September 16, 2026
Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 12, 2026
Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer
August 11, 2026
Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535
July 6, 2026
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
June 29, 2026
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
June 4, 2026
Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
May 28, 2026
Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates
May 25, 2026
Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 19, 2026
Kailera Therapeutics Announces Pricing of Initial Public Offering
April 16, 2026